Anti-hCD19-CD3Anti-hCD19-CD3Unit sizeCat. codeDocsPriceBispecific antibody against human CD19 and human CD310 µg bimab-hcd19cd3TDSMSDSDATA ￥4,586.00Please contact our distributorAdd to favoriteAboutSpecificationsContentsRelated productsMonoclonal scFv antibody against human CD19 and human CD3Anti-hCD19-CD3 is a bispecific antibody that recognizes two human cell markers: hCD19, which is expressed on the surface of B cells, and hCD3 which is part of the T cell receptor. This antibody features Blinatumomab single-chain variable fragments (scFv) joined by a glycine-serine linker. These two scFvs have been cloned from the anti-hCD19 (clone HD37) and anti-hCD3 (clone L2K-07) monoclonal antibodies [1,2]. Blinatumomab is used for the treatment of refractory acute lymphocytic leukemia (ALL) in clinics. By binding to hCD3 and hCD19, Blinatumomab engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [2]. Blinatumomab does not cross‑react with CD3 and CD19 from mice, rats, or dogs [3].Anti-hCD19-CD3 bispecific antibody can be used for fine-tuning studies of B cell contact-dependent killing and T cell activation/proliferation.Negative control antibodies are also available from InvivoGen: Anti-hCD19-βGal and Anti-βGal-hCD3. References:1. Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.2. Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7. 3. Trivedi A. et al., 2017. Clinical Pharmacology and Translational Aspects of Bispecific Antibodies. Clin Transl Sci. 10(3):147-162. Figures Jurkat-Lucia™ NFAT cell activation upon incubation with Raji B cells and Anti-hCD19-CD3.(A) Raji cells were pre-incubated with Anti-hCD19-CD3, or the two bispecific negative controls Anti-β-Gal-hCD3 and Anti-hCD19-β-Gal for 30 minutes before addition of Jurkat-Lucia™ NFAT cells. After 8 hours incubation, T cell activation was determined by measuring the Lucia luciferase activity using QUANTI-Luc™ detection reagent. Results are presented as relative activity expressed as a percentage of Lucia activity in samples with the highest dose of antibody.(B) Target specificity of Anti-hCD19-CD3 was verified upon incubation with Jurkat-Lucia™ NFAT cells and Raji cells as described in (A), with Jurkat-Lucia™ NFAT cells only, or with Raji cells only. T cell activation was determined by measuring the Lucia luciferase activity using QUANTI-Luc™ and expressed as relative light units (RLUs). Back to the topSpecificationsClonality: Monoclonal antibody.Specificity: Targets cells expressing human CD19 and human CD3.Isotype: none (scFv).Source: CHO (Chinese hamster ovary) cells.Purity: > 90% Purified by affinity chromatography.Quality control:    Binding to hCD19 and to hCD3 has been confirmed by flow cytometry.   Biological activity has been confirmed using cellular assays.   The complete sequence of this antibody has been verified.   The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.Back to the topContents10 µg Anti-hCD19-CD3, purified antibody, provided azide-free and lyophilized. Product is shipped at room temperature. Store lyophilized antibody at -20°C. Lyophilized product is stable for at least 1 year.Back to the topYou may also needAnti-βGal-hCD3Bispecific antibody against β-Gal and human CD3; Negative controlAnti-hCD19-βGalBispecific antibody against human CD19 and β-Gal; Negative controlJurkat-Lucia™ NFAT CellsNFAT-Luc Reporter T LymphocytesQUANTI-Luc™ GoldCoelenterazine-based luminescence detection kit for standard and HTS assays